Novan, Inc. (NASDAQ:NOVN) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain OfficersItem 5.02.
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
(b) Resignation of Officer
On May 2, 2017, M. Joyce Rico, Chief Medical Officer of Novan, Inc. (the “Company”), notified the Company of her decision to resign. On May 5, 2017, the Company and Dr. Rico reached agreement regarding her departure from the Company effective May 5, 2017, for “Good Reason” (as defined in the employment agreement, dated August 25, 2016 between Dr. Rico and the Company).
About Novan, Inc. (NASDAQ:NOVN)
Novan, Inc. is a late-stage pharmaceutical company. The Company is engaged in the development and commercialization of therapies using its nitric oxide platform. The Company develops product candidates using its Nitricil technology, which enables the Company to engineer tunable new chemical entities (NCEs). The Company’s formulation science enables it to further tune the release of nitric oxide when applied to the skin by using the combinations of inactive ingredients. It is developing SB204 for the treatment of acne vulgaris in Phase III. The Company is developing its product candidate, SB206, for the treatment of external genital and perianal warts in Phase II. It is developing SB208, an investigational topical anti-fungal for the treatment of fungal infections of the skin and nails. It is developing SB204 for the treatment of inflammatory skin diseases. Its pipeline also includes SB414, a topical cream product candidate. Novan, Inc. (NASDAQ:NOVN) Recent Trading Information
Novan, Inc. (NASDAQ:NOVN) closed its last trading session down -0.02 at 4.98 with 60,397 shares trading hands.
